Baidu
map

Cancer Cell:癌症领域的“两面派”?抑癌蛋白也可能助癌

2019-02-03 佚名 新华社

一种名为p53的蛋白质因有助抗癌,一直被视为抵御癌症的“守护者”。不过一项新研究发现,这种蛋白质可能是“两面派”,在某些情况下,反而会为癌细胞提供能量,充当肿瘤生长的“帮凶”。

一种名为p53的蛋白质因有助抗癌,一直被视为抵御癌症的“守护者”。不过一项新研究发现,这种蛋白质可能是“两面派”,在某些情况下,反而会为癌细胞提供能量,充当肿瘤生长的“帮凶”。

由p53基因编码的p53蛋白是癌症研究领域的“明星”。此前发现它能抑制癌细胞产生,作为一种抑癌蛋白质被广泛关注。但研究也发现它的“疑点”,比如尽管在多半癌症种类中,都发现了与这种蛋白相关的p53基因突变,但在肝癌等患者体内,通常却不存在这种突变。

美国加利福尼亚大学圣迭戈分校研究人员领导的一个国际团队,结合细胞样本、实验鼠模型和人类患者进行了一项综合研究。结果发现,p53蛋白能提高肿瘤代谢水平,促进肿瘤生长。具体来说,p53会间接作为癌细胞凋亡的调节器,在癌细胞的能量中枢线粒体中发挥作用,通过“糖酵解”作用为本该凋亡的癌细胞提供替代性能量。

研究人员认为,在抑制癌细胞产生方面,p53确实能发挥积极作用,这主要是通过降低细胞的“氧化磷酸化”作用从而减少毒素的生成。然而一旦肿瘤形成,p53的作用就会“反转”,加速肿瘤的生长恶化。

相关论文发表在新一期美国《癌细胞》杂志上。研究人员认为,这一新发现为相关药物研发提供了警示,特别是尝试利用p53抑癌机制的抗癌药应当注意可能产生的副作用。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1640665, encodeId=b6801640665e0, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Sat Jun 15 10:15:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780769, encodeId=b5df1e80769e2, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Oct 28 12:15:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961404, encodeId=7b7f19614045c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Dec 12 10:15:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871127, encodeId=93bb18e112784, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 13 16:15:00 CST 2019, time=2019-10-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1640665, encodeId=b6801640665e0, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Sat Jun 15 10:15:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780769, encodeId=b5df1e80769e2, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Oct 28 12:15:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961404, encodeId=7b7f19614045c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Dec 12 10:15:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871127, encodeId=93bb18e112784, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 13 16:15:00 CST 2019, time=2019-10-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1640665, encodeId=b6801640665e0, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Sat Jun 15 10:15:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780769, encodeId=b5df1e80769e2, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Oct 28 12:15:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961404, encodeId=7b7f19614045c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Dec 12 10:15:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871127, encodeId=93bb18e112784, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 13 16:15:00 CST 2019, time=2019-10-13, status=1, ipAttribution=)]
    2019-12-12 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1640665, encodeId=b6801640665e0, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Sat Jun 15 10:15:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780769, encodeId=b5df1e80769e2, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Oct 28 12:15:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961404, encodeId=7b7f19614045c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Dec 12 10:15:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871127, encodeId=93bb18e112784, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 13 16:15:00 CST 2019, time=2019-10-13, status=1, ipAttribution=)]

相关资讯

Dev Cell:这种几乎无药可治的乳腺癌,竟然有了新靶点?

在乳腺癌里,有一种分类叫做“三阴性乳腺癌”。它并不常见,大概只占乳腺癌总数的10%。但它造成的死亡病例,却占到了乳腺癌患者死亡数的四分之一!

Baidu
map
Baidu
map
Baidu
map